Ketoconazole
- Generic Name
- Ketoconazole
- Brand Names
- Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28Cl2N4O4
- CAS Number
- 65277-42-1
- Unique Ingredient Identifier
- R9400W927I
- Background
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...
- Indication
Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.
- Associated Conditions
- Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
- Associated Therapies
- -
A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01267084
A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01240226
- Locations
- 🇺🇸
Investigational Site, Austin, Texas, United States
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT01218620
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole
- Conditions
- Interventions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT01165125
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study of RO5190591 (Danoprevir) in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01164488
Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- CrystalGenomics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01154764
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Relative Bioavailability of of Olodaterol and Ketoconazole
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT01153711
- Locations
- 🇩🇪
1222.47.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01149785
- Locations
- 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States
Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01124760
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 12
- Registration Number
- NCT01114191
- Locations
- 🇺🇸
Site Reference ID/Investigator# 35784, Detroit, Michigan, United States
🇺🇸Site Reference ID/Investigator# 36527, Lebanon, New Hampshire, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.